




**Prospera™**  
Transplant assessment

# Partner with us to help your patients thrive and prosper


A kidney transplant can feel like getting another chance at life. That's why taking care of a patient's new kidney is of utmost importance.



**The ProActive Study For Kidney Transplant Patients**  
Prospera for Active Rejection

# We can advance innovation in organ transplant care

Together with you and other partners in the ProActive Study, we will generate insights that enable earlier, more precise assessment of allograft rejection. Over time, these insights hold the promise to improve the lives of renal transplant patients everywhere.



## ORGAN REJECTION IS A PROBLEM

Many kidney transplant failures occur within the first five to ten years<sup>3,4</sup> because organ rejection isn't caught early enough and treated effectively. As a result, the patient needs a new organ and must start the waitlist process again.

# Let's improve the management of transplant patients

Prospera™ and the ProActive Study have the power and potential to change transplant patient management for good. The study will follow approximately 3,000 renal transplant patients over three years to evaluate the impact of the Prospera transplant assessment test across three critical measures:


**1** Management through effective use of biopsy

**2** Outcomes including improved graft survival

**3** Ability to identify subclinical and clinical rejection compared to serum creatinine

## Our core technology

Prospera is designed to assess kidney transplant damage by evaluating the percentage of donor-derived cell-free DNA (dd-cfDNA) in a transplant recipient's blood. Too much donor-derived dd-cfDNA in the recipient's blood is an early indication of potential organ rejection.



Supplementing the current standards of monitoring (i.e., regular biopsies, evaluation of serum creatinine), Prospera is intended to evaluate kidney rejection status to help you:

- **Eliminate unnecessary biopsies resulting from inaccurate tests**
- **Make treatment more timely**
- **Personalize immunosuppression therapy**

### The Prospera transplant assessment test is:

Simpler and less invasive than biopsy;  
no donor genotyping required

Suitable for most renal allograft patients  
across ethnicities

More sensitive and specific for clinical and  
subclinical active rejection than serum creatinine<sup>5</sup>

## PROACTIVE STUDY ELIGIBILITY



### Inclusion Criteria

Must be willing to provide informed consent

Must be a kidney transplant recipient



### Exclusion Criteria

Other non-kidney transplanted organ(s)

Pregnant

Genetically identical donor organs

# Together, we can help patients thrive and prosper

We need your help. Natera is applying its experience of performing over 1.5 million cell-free DNA tests in the prenatal setting to the complex world of transplantation. Thought leaders like you are essential to successfully advancing the management of post-kidney transplantation through innovation. Your participation in the ProActive Study contributes to the exploration of cell-free DNA's potential to assess the health of a transplanted organ.

1 Organ Donation Statistics. U.S. Department of Health and Human Services. U.S. Government Information on Organ Donation and Transplantation. <https://www.organdonor.gov/statistics-stories/statistics.html>. Published March 31, 2016.

2 Kidney Disease Statistics for the United States. National Institute of Diabetes and Digestive and Kidney Diseases. <https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease>. Published Dec. 1, 2016.

3 Stegall et al, Through a Glass Darkly: Seeking Clarity in Preventing Late Kidney Transplant Failure, *J Am Soc Nephrol*. 2015; 26 (1):20-9

4 Lamb et al, Long-term renal allograft survival in the United States: a critical reappraisal, *Am J of Transplantation*. 2011;

Mar;11(3):450-62.5. Altug, et al.

5 Sigdel TK, et al. *J. Clin. Med.* 2019, 8, 19.

This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.

© 2019 Natera, Inc. PRO\_ATC\_PhysicianRegistry\_20190524\_NAT-801957

For more information, visit:  
[natera.com/prospera](https://natera.com/prospera)  
[joinproactivestudy.com](https://joinproactivestudy.com)

 **natera**<sup>®</sup>  
Conceive. Deliver. Thrive.

## The ProActive Study For Kidney Transplant Patients

Prospera for Active Rejection

# IMAGINE

a future where your kidney transplant patients live longer, healthier lives thanks to more timely actions to prevent kidney graft failure. Imagine relying on just a simple blood test for an earlier, more comprehensive picture of transplanted kidney health.

# TOGETHER

we can provide important benefits for your transplant patients: truly meaningful hope for greater longevity and the best quality of life possible.



**Prospera™**  
Transplant assessment

